<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01674621</url>
  </required_header>
  <id_info>
    <org_study_id>BA058-05-007</org_study_id>
    <secondary_id>2012-001921-29</secondary_id>
    <nct_id>NCT01674621</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of BA058 (Abaloparatide) Administered Via a Coated Transdermal Microarray Delivery System (BA058 Transdermal (Abaloparatide Transdermal)) in Healthy Postmenopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Bioscience A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radius Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the clinical safety and efficacy of BA058 Transdermal in otherwise healthy
      postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD)
      and serum markers of bone metabolism when compared to Transdermal Placebo and BA058 Injection
      for 6 months of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BMD (Lumbar Spine)</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in BMD, using DXA results; active compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMD (Total Hip and Forearm)</measure>
    <time_frame>6 Months</time_frame>
    <description>Change in BMD, using DXA results; active compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Markers of Bone Formation and Resorption</measure>
    <time_frame>6 months</time_frame>
    <description>Change in laboratory results; active compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>6 Months</time_frame>
    <description>Physical examinations, vital signs, electrocardiograms, clinical laboratory tests, local tolerance, and adverse events.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Post Menopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>BA058 (abaloparatide) Transdermal Placebo (0 mcg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BA058 (abaloparatide) Transdermal Microneedle Patch 0 mcg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA058 (abaloparatide) Transdermal (50 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BA058 (abaloparatide)Transdermal Microneedle Patch - 50 mcg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA058 (abaloparatide) Transdermal (100 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BA058 (abaloparatide) Transdermal Microneedle Patch - 100 mcg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA058 (abaloparatide) Transdermal (150 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BA058 (abaloparatide) Transdermal Microneedle Patch - 150 mcg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA058 (abaloparatide) Injection (80 mcg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BA058 (abaloparatide-SC) Subcutaneous Injection - 80 mcg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BA058 Placebo</intervention_name>
    <description>BA058 Transdermal Microneedle Placebo Patch, 0 mcg, daily applications for 6 months</description>
    <arm_group_label>BA058 (abaloparatide) Transdermal Placebo (0 mcg)</arm_group_label>
    <other_name>abaloparatide Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BA058 Transdermal (50 mcg)</intervention_name>
    <description>BA058 Transdermal Microneedle Active Patch, 50 mcg, daily applications for 6 months</description>
    <arm_group_label>BA058 (abaloparatide) Transdermal (50 mcg)</arm_group_label>
    <other_name>abaloparatide Transdermal (50 mcg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BA058 Transdermal (100 mcg)</intervention_name>
    <description>BA058 Transdermal Microneedle Active Patch, 100 mcg, daily applications for 6 months</description>
    <arm_group_label>BA058 (abaloparatide) Transdermal (100 mcg)</arm_group_label>
    <other_name>abaloparatide Transdermal (100 mcg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BA058 Transdermal (150 mcg)</intervention_name>
    <description>BA058 Transdermal Microneedle Active Patch, 150 mcg, daily applications for 6 months</description>
    <arm_group_label>BA058 (abaloparatide) Transdermal (150 mcg)</arm_group_label>
    <other_name>abaloparatide Transdermal (150 mcg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BA058 Injection (80 mcg)</intervention_name>
    <description>BA058 Subcutaneous Injection, 80 mcg, daily injections for 6 months</description>
    <arm_group_label>BA058 (abaloparatide) Injection (80 mcg)</arm_group_label>
    <other_name>abaloparatide Injection (80 mcg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal woman, less than 85 years old.

          -  BMD T-score ≤ -2.5 of spine or hip (femoral neck) or ≤ -2.0 with previous fracture
             (within 5 years).

          -  Normal physical exam, vital signs, electrocardiogram (ECG) and medical history.

          -  Laboratory tests within the normal range including serum calcium, Vit D, PTH(1-84),
             serum phosphorus and alkaline phosphatase.

        Exclusion Criteria:

          -  BMD T-score ≤ -5.0 at the lumbar spine or hip.

          -  History of bone disorders (e.g., Paget's disease) other than postmenopausal
             osteoporosis.

          -  Significantly impaired renal function.

          -  History of any cancer.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ballerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vejie</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
  </removed_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2012</study_first_submitted>
  <study_first_submitted_qc>August 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2012</study_first_posted>
  <results_first_submitted>October 25, 2016</results_first_submitted>
  <results_first_submitted_qc>October 25, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2016</results_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BA058</keyword>
  <keyword>Abaloparatide-SC</keyword>
  <keyword>abaloparatide</keyword>
  <keyword>Abaloparatide-TD</keyword>
  <keyword>Osteo</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Transdermal</keyword>
  <keyword>Patch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BA058 (Abaloparatide) Transdermal Placebo (0 mcg)</title>
          <description>BA058 (abaloparatide) Transdermal Microneedle Patch 0 mcg daily
BA058 Placebo: BA058 Transdermal Microneedle Placebo Patch, 0 mcg, daily applications for 6 months</description>
        </group>
        <group group_id="P2">
          <title>BA058 (Abaloparatide) Transdermal (50 mcg)</title>
          <description>BA058 (abaloparatide)Transdermal Microneedle Patch - 50 mcg daily
BA058 Transdermal (50 mcg): BA058 Transdermal Microneedle Active Patch, 50 mcg, daily applications for 6 months</description>
        </group>
        <group group_id="P3">
          <title>BA058 (Abaloparatide) Transdermal (100 mcg)</title>
          <description>BA058 (abaloparatide) Transdermal Microneedle Patch - 100 mcg daily
BA058 Transdermal (100 mcg): BA058 Transdermal Microneedle Active Patch, 100 mcg, daily applications for 6 months</description>
        </group>
        <group group_id="P4">
          <title>BA058 (Abaloparatide) Transdermal (150 mcg)</title>
          <description>BA058 (abaloparatide) Transdermal Microneedle Patch - 150 mcg daily
BA058 Transdermal (150 mcg): BA058 Transdermal Microneedle Active Patch, 150 mcg, daily applications for 6 months</description>
        </group>
        <group group_id="P5">
          <title>BA058 (Abaloparatide) Injection (80 mcg)</title>
          <description>BA058 (abaloparatide-SC) Subcutaneous Injection - 80 mcg daily
BA058 Injection (80 mcg): BA058 Subcutaneous Injection, 80 mcg, daily injections for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="48"/>
                <participants group_id="P5" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BA058 (Abaloparatide) Transdermal Placebo (0 mcg)</title>
          <description>BA058 (abaloparatide) Transdermal Microneedle Patch 0 mcg daily
BA058 Placebo: BA058 Transdermal Microneedle Placebo Patch, 0 mcg, daily applications for 6 months</description>
        </group>
        <group group_id="B2">
          <title>BA058 (Abaloparatide) Transdermal (50 mcg)</title>
          <description>BA058 (abaloparatide)Transdermal Microneedle Patch - 50 mcg daily
BA058 Transdermal (50 mcg): BA058 Transdermal Microneedle Active Patch, 50 mcg, daily applications for 6 months</description>
        </group>
        <group group_id="B3">
          <title>BA058 (Abaloparatide) Transdermal (100 mcg)</title>
          <description>BA058 (abaloparatide) Transdermal Microneedle Patch - 100 mcg daily
BA058 Transdermal (100 mcg): BA058 Transdermal Microneedle Active Patch, 100 mcg, daily applications for 6 months</description>
        </group>
        <group group_id="B4">
          <title>BA058 (Abaloparatide) Transdermal (150 mcg)</title>
          <description>BA058 (abaloparatide) Transdermal Microneedle Patch - 150 mcg daily
BA058 Transdermal (150 mcg): BA058 Transdermal Microneedle Active Patch, 150 mcg, daily applications for 6 months</description>
        </group>
        <group group_id="B5">
          <title>BA058 (Abaloparatide) Injection (80 mcg)</title>
          <description>BA058 (abaloparatide-SC) Subcutaneous Injection - 80 mcg daily
BA058 Injection (80 mcg): BA058 Subcutaneous Injection, 80 mcg, daily injections for 6 months</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="46"/>
            <count group_id="B4" value="43"/>
            <count group_id="B5" value="49"/>
            <count group_id="B6" value="231"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.5" spread="7.27"/>
                    <measurement group_id="B2" value="65.9" spread="4.83"/>
                    <measurement group_id="B3" value="65.7" spread="5.26"/>
                    <measurement group_id="B4" value="66.3" spread="6.46"/>
                    <measurement group_id="B5" value="66.4" spread="5.48"/>
                    <measurement group_id="B6" value="66.2" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>BMD (Lumbar Spine)</title>
        <description>Change in BMD, using DXA results; active compared to placebo.</description>
        <time_frame>6 Months</time_frame>
        <population>Modified intent-to-treat population included all patients with pre-treatment and end-of-treatment evaluable DXA assessments. The patients are analyzed as randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>BA058 (Abaloparatide) Transdermal Placebo (0 mcg)</title>
            <description>BA058 (abaloparatide) Transdermal Microneedle Patch 0 mcg daily
BA058 Placebo: BA058 Transdermal Microneedle Placebo Patch, 0 mcg, daily applications for 6 months</description>
          </group>
          <group group_id="O2">
            <title>BA058 (Abaloparatide) Transdermal (50 mcg)</title>
            <description>BA058 (abaloparatide)Transdermal Microneedle Patch - 50 mcg daily
BA058 Transdermal (50 mcg): BA058 Transdermal Microneedle Active Patch, 50 mcg, daily applications for 6 months</description>
          </group>
          <group group_id="O3">
            <title>BA058 (Abaloparatide) Transdermal (100 mcg)</title>
            <description>BA058 (abaloparatide) Transdermal Microneedle Patch - 100 mcg daily
BA058 Transdermal (100 mcg): BA058 Transdermal Microneedle Active Patch, 100 mcg, daily applications for 6 months</description>
          </group>
          <group group_id="O4">
            <title>BA058 (Abaloparatide) Transdermal (150 mcg)</title>
            <description>BA058 (abaloparatide) Transdermal Microneedle Patch - 150 mcg daily
BA058 Transdermal (150 mcg): BA058 Transdermal Microneedle Active Patch, 150 mcg, daily applications for 6 months</description>
          </group>
          <group group_id="O5">
            <title>BA058 (Abaloparatide) Injection (80 mcg)</title>
            <description>BA058 (abaloparatide-SC) Subcutaneous Injection - 80 mcg daily
BA058 Injection (80 mcg): BA058 Subcutaneous Injection, 80 mcg, daily injections for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>BMD (Lumbar Spine)</title>
          <description>Change in BMD, using DXA results; active compared to placebo.</description>
          <population>Modified intent-to-treat population included all patients with pre-treatment and end-of-treatment evaluable DXA assessments. The patients are analyzed as randomized.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="2.47"/>
                    <measurement group_id="O2" value="1.87" spread="2.87"/>
                    <measurement group_id="O3" value="2.33" spread="2.96"/>
                    <measurement group_id="O4" value="2.95" spread="3.13"/>
                    <measurement group_id="O5" value="5.80" spread="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BMD (Total Hip and Forearm)</title>
        <description>Change in BMD, using DXA results; active compared to placebo.</description>
        <time_frame>6 Months</time_frame>
        <population>Modified intent-to-treat population included all patients with pre-treatment and end-of-treatment evaluable DXA assessments. The patients are analyzed as randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>BA058 (Abaloparatide) Transdermal Placebo (0 mcg)</title>
            <description>BA058 (abaloparatide) Transdermal Microneedle Patch 0 mcg daily
BA058 Placebo: BA058 Transdermal Microneedle Placebo Patch, 0 mcg, daily applications for 6 months</description>
          </group>
          <group group_id="O2">
            <title>BA058 (Abaloparatide) Transdermal (50 mcg)</title>
            <description>BA058 (abaloparatide)Transdermal Microneedle Patch - 50 mcg daily
BA058 Transdermal (50 mcg): BA058 Transdermal Microneedle Active Patch, 50 mcg, daily applications for 6 months</description>
          </group>
          <group group_id="O3">
            <title>BA058 (Abaloparatide) Transdermal (100 mcg)</title>
            <description>BA058 (abaloparatide) Transdermal Microneedle Patch - 100 mcg daily
BA058 Transdermal (100 mcg): BA058 Transdermal Microneedle Active Patch, 100 mcg, daily applications for 6 months</description>
          </group>
          <group group_id="O4">
            <title>BA058 (Abaloparatide) Transdermal (150 mcg)</title>
            <description>BA058 (abaloparatide) Transdermal Microneedle Patch - 150 mcg daily
BA058 Transdermal (150 mcg): BA058 Transdermal Microneedle Active Patch, 150 mcg, daily applications for 6 months</description>
          </group>
          <group group_id="O5">
            <title>BA058 (Abaloparatide) Injection (80 mcg)</title>
            <description>BA058 (abaloparatide-SC) Subcutaneous Injection - 80 mcg daily
BA058 Injection (80 mcg): BA058 Subcutaneous Injection, 80 mcg, daily injections for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>BMD (Total Hip and Forearm)</title>
          <description>Change in BMD, using DXA results; active compared to placebo.</description>
          <population>Modified intent-to-treat population included all patients with pre-treatment and end-of-treatment evaluable DXA assessments. The patients are analyzed as randomized.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change from baseline in BMD of total hip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="2.39"/>
                    <measurement group_id="O2" value="0.97" spread="1.95"/>
                    <measurement group_id="O3" value="1.32" spread="1.96"/>
                    <measurement group_id="O4" value="1.49" spread="1.73"/>
                    <measurement group_id="O5" value="2.7377" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change from baseline in BMD of forearm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="3.18"/>
                    <measurement group_id="O2" value="-0.24" spread="2.74"/>
                    <measurement group_id="O3" value="-0.16" spread="3.71"/>
                    <measurement group_id="O4" value="0.84" spread="2.96"/>
                    <measurement group_id="O5" value="0.33" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Markers of Bone Formation and Resorption</title>
        <description>Change in laboratory results; active compared to placebo.</description>
        <time_frame>6 months</time_frame>
        <population>Modified intent-to-treat population included all patients with pre-treatment and end-of-treatment evaluable DXA assessments. The patients are analyzed as randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>BA058 (Abaloparatide) Transdermal Placebo (0 mcg)</title>
            <description>BA058 (abaloparatide) Transdermal Microneedle Patch 0 mcg daily
BA058 Placebo: BA058 Transdermal Microneedle Placebo Patch, 0 mcg, daily applications for 6 months</description>
          </group>
          <group group_id="O2">
            <title>BA058 (Abaloparatide) Transdermal (50 mcg)</title>
            <description>BA058 (abaloparatide)Transdermal Microneedle Patch - 50 mcg daily
BA058 Transdermal (50 mcg): BA058 Transdermal Microneedle Active Patch, 50 mcg, daily applications for 6 months</description>
          </group>
          <group group_id="O3">
            <title>BA058 (Abaloparatide) Transdermal (100 mcg)</title>
            <description>BA058 (abaloparatide) Transdermal Microneedle Patch - 100 mcg daily
BA058 Transdermal (100 mcg): BA058 Transdermal Microneedle Active Patch, 100 mcg, daily applications for 6 months</description>
          </group>
          <group group_id="O4">
            <title>BA058 (Abaloparatide) Transdermal (150 mcg)</title>
            <description>BA058 (abaloparatide) Transdermal Microneedle Patch - 150 mcg daily
BA058 Transdermal (150 mcg): BA058 Transdermal Microneedle Active Patch, 150 mcg, daily applications for 6 months</description>
          </group>
          <group group_id="O5">
            <title>BA058 (Abaloparatide) Injection (80 mcg)</title>
            <description>BA058 (abaloparatide-SC) Subcutaneous Injection - 80 mcg daily
BA058 Injection (80 mcg): BA058 Subcutaneous Injection, 80 mcg, daily injections for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Markers of Bone Formation and Resorption</title>
          <description>Change in laboratory results; active compared to placebo.</description>
          <population>Modified intent-to-treat population included all patients with pre-treatment and end-of-treatment evaluable DXA assessments. The patients are analyzed as randomized.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent change from baseline of BSAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.23" spread="64.93"/>
                    <measurement group_id="O2" value="-4.84" spread="23.87"/>
                    <measurement group_id="O3" value="5.22" spread="43.66"/>
                    <measurement group_id="O4" value="-5.52" spread="37.86"/>
                    <measurement group_id="O5" value="17.30" spread="42.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change from baseline of osteoclacin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.21" spread="27.55"/>
                    <measurement group_id="O2" value="-4.37" spread="19.36"/>
                    <measurement group_id="O3" value="6.67" spread="33.38"/>
                    <measurement group_id="O4" value="-3.83" spread="22.01"/>
                    <measurement group_id="O5" value="69.54" spread="81.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change from baseline of P1CP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.76" spread="31.35"/>
                    <measurement group_id="O2" value="-17.26" spread="22.86"/>
                    <measurement group_id="O3" value="-8.42" spread="29.51"/>
                    <measurement group_id="O4" value="-16.63" spread="25.11"/>
                    <measurement group_id="O5" value="10.28" spread="72.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change from baseline of P1NP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.26" spread="35.49"/>
                    <measurement group_id="O2" value="-12.76" spread="26.81"/>
                    <measurement group_id="O3" value="1.52" spread="57.29"/>
                    <measurement group_id="O4" value="-6.78" spread="38.91"/>
                    <measurement group_id="O5" value="97.64" spread="172.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent change from baseline of CTX1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.42" spread="22.57"/>
                    <measurement group_id="O2" value="-2.61" spread="28.77"/>
                    <measurement group_id="O3" value="1.65" spread="48.66"/>
                    <measurement group_id="O4" value="-8.22" spread="54.84"/>
                    <measurement group_id="O5" value="41.11" spread="104.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability</title>
        <description>Physical examinations, vital signs, electrocardiograms, clinical laboratory tests, local tolerance, and adverse events.</description>
        <time_frame>6 Months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>BA058 (Abaloparatide) Transdermal Placebo (0 mcg)</title>
          <description>BA058 (abaloparatide) Transdermal Microneedle Patch 0 mcg daily
BA058 Placebo: BA058 Transdermal Microneedle Placebo Patch, 0 mcg, daily applications for 6 months</description>
        </group>
        <group group_id="E2">
          <title>BA058 (Abaloparatide) Transdermal (50 mcg)</title>
          <description>BA058 (abaloparatide)Transdermal Microneedle Patch - 50 mcg daily
BA058 Transdermal (50 mcg): BA058 Transdermal Microneedle Active Patch, 50 mcg, daily applications for 6 months</description>
        </group>
        <group group_id="E3">
          <title>BA058 (Abaloparatide) Transdermal (100 mcg)</title>
          <description>BA058 (abaloparatide) Transdermal Microneedle Patch - 100 mcg daily
BA058 Transdermal (100 mcg): BA058 Transdermal Microneedle Active Patch, 100 mcg, daily applications for 6 months</description>
        </group>
        <group group_id="E4">
          <title>BA058 (Abaloparatide) Transdermal (150 mcg)</title>
          <description>BA058 (abaloparatide) Transdermal Microneedle Patch - 150 mcg daily
BA058 Transdermal (150 mcg): BA058 Transdermal Microneedle Active Patch, 150 mcg, daily applications for 6 months</description>
        </group>
        <group group_id="E5">
          <title>BA058 (Abaloparatide) Injection (80 mcg)</title>
          <description>BA058 (abaloparatide-SC) Subcutaneous Injection - 80 mcg daily
BA058 Injection (80 mcg): BA058 Subcutaneous Injection, 80 mcg, daily injections for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalciuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Results may not be published prior to the Study Report completion. Investigators may publish results, providing a manuscript to the Sponsor =/&gt; 30 days prior to its submission to a publisher. Sponsor will provide manuscript to Investigators =/&gt; 30 days prior to its submission. Investigator shall comply with Sponsor's policy, withholding publication for an additional 60 days to permit the Sponsor to obtain patent or other proprietary rights protection, if deemed necessary.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Program Director</name_or_title>
      <organization>Radius Health Inc.</organization>
      <phone>(617) 551-4700</phone>
      <email>info@radiuspharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

